George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.82
Bid: 3.70
Ask: 3.94
Change: 0.01 (0.26%)
Spread: 0.24 (6.486%)
Open: 3.81
High: 0.00
Low: 0.00
Prev. Close: 3.81
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PREtec Products Submitted for Regulatory Approval

25 Sep 2023 07:00

RNS Number : 4159N
Plant Health Care PLC
25 September 2023
 

25 September 2023

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

New PREtec Products Submitted for Regulatory Approval

 

PHC25279 and PHC68949 submitted for approval in Mexico

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce it has submitted applications to the Mexican regulatory agency for approval to commercialize the newest products derived from the Company's PREtec technology platform (Vaccines for PlantsTM), PHC25279 and PHC68949, for use on major crops. 

 

PHC25279 helps control a broad spectrum of plant diseases when used as part of an integrated disease control program and is expected to find immediate application for the control of Gray Mold (Botrytis cinerea) in berries, Downy Mildew (Pseudoperonospora cubensis) in cucurbits such as cucumbers and Late Blight (Phytothphora infestans) in tomatoes and other Solanaceae crops. The current planted area in Mexico for berries totals 55,000 hectares. The production of cucumbers in Mexico is expected to reach 1.02 million metric tons by 2026. Additional PHC25279 product label claims against various other plant pathogens will be added in the future. 

 

PHC68949 is a novel product that amplifies a plant's natural defense pathways to provide protection against plant parasitic nematodes which damage plant roots and limit crop yield. As a next generation bionematicide, PHC68949 increases plant health and yield across a wide range of commercial crops. Results from field studies confirm the efficacy from foliar applications of PHC68949 is comparable to synthetic chemical nematicides and superior to current biological products. PHC68949 is expected to find immediate use in tomatoes, eggplants, peppers and other crops within the Solanaceae family and in cucurbits to protect against yield and quality losses caused by root knot nematodes (Meloidogyne spp.) and other pathogenic nematode species. Mexico's 2023 fresh tomato production is forecasted to reach 3.4 million metric tons (MMT). Additional PHC68949 product label claims against plant parasitic nematodes will be added in the future. 

 

Both products are based on the Company's PREtec technology platform (Vaccines for PlantsTM). Derived from natural proteins, PREtec is an environmentally friendly technology which stimulates plant defense and pathogen resistance mechanisms within plants, resulting in improved crop growth and quality along with the ability to withstand a variety of abiotic stresses. PHC25279 and PHC68949 represent unique products from this platform which provide specific benefits of improved disease and nematode control, plant health and yield. PREtec peptides are compatible with mainstream agricultural practices and common IPM (Integrated Pest Management) and resistance management practices.

 

The regulatory process in Mexico for agricultural products involves a detailed and comprehensive review of standard data requirements. Upon approval, the Federal Committee for Protection from Sanitary Risks (COFEPRIS) will issue Federal Registration. Although COFEPRIS does not commit to a specific timeline for granting regulatory licenses, the Company expects the review to start soon and to receive regulatory approvals within 1-2 years.

 

Plant Health Care continues to expand into new markets around the world and is growing its relationships with major global distribution partners. The Company is on track to achieve revenue of $30 million by 2025 through the launch of new products and continued organic business growth through current and future distributor relationships.

 

Jeff Tweedy, CEO of Plant Health Care, said: ‟Ranking 11th in global food production, Mexico provides a tremendous opportunity for the adoption of these new products to support sustainable agriculture. Building on the current success of our ProAct biostimulant, our dedicated team in Mexico is already laying the groundwork for the commercial launch of these two new products once the regulatory licenses are granted. These registration submissions are key steps for Plant Health Care in meeting our $30 million revenue target by 2025."

 

For further information, please contact: 

Plant Health Care plc Jeff Tweedy, CEO

+1 919 926 1600

Cavendish Securities plc - Nomad & Broker Neil McDonald / Pete Lynch

+44 (0) 131 220 9771

SEC Newgate - Financial Communications Robin Tozer / Harry Handyside / George Esmond

+44 (0)7540 106 366 phc@secnewgate.co.uk

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAPBSGDCBSDDGXD
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.